Scaling From Clinical To Commercial With The Same CDMO: Pros, Pitfalls, And How To Plan

Transitioning from clinical development to commercial manufacturing is a pivotal moment in any drug development program, requiring careful strategic planning and informed decision-making. One of the most critical choices sponsors face is whether to continue with their existing contract development and manufacturing organization (CDMO) or switch to a new partner. While continuity can offer significant advantages—such as retained institutional knowledge, established working relationships, and operational efficiencies—it is not without risk. Not all CDMOs are equipped to support commercial-scale production, and limitations in capacity, infrastructure, or regulatory experience can create significant challenges. Evaluating commercial readiness early, including equipment capabilities, analytical support, and inspection history, is essential to avoiding delays. Additionally, the true cost and complexity of technology transfer are often underestimated, making early planning vital. Ultimately, a deliberate, well-informed approach helps sponsors minimize risk, control costs, and support successful product launches.